Local Institution

Clichy 92118

0 studies enrolling now · 20 studies all time

What they study most

Chronic Hepatitis C, Colitis, Ulcerative, Crohn's Disease, Hepatitis B, Hepatitis B Virus, Hepatitis B, Chronic, Hepatitis C, Hepatitis C Virus, Hepatitis C Virus (HCV), Hepatitis C Virus Infection, Hepato Cellular Carcinoma (HCC), Hepatocellular Carcinoma

Studies at this site

• Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
• Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin — Completed
• Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care — Completed
• Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen — Completed
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
• Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy — Completed
• Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial — Completed
• A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
• Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation — Completed
• Belatacept in Liver Transplant Recipients — Stopped early
• Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection — Completed